JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

Search

Boston Scientific Corp.

Cerrado

SectorSanidad

62.08 -5.77

Resumen

Variación precio

24h

Actual

Mínimo

62

Máximo

62.96

Métricas clave

By Trading Economics

Ingresos

-83M

672M

Ventas

221M

5.3B

P/B

Media del Sector

31.438

60.328

Margen de beneficios

12.713

Empleados

59,000

EBITDA

-412M

956M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+45.64% upside

Dividendos

By Dow Jones

Próximas Ganancias

22 jul 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-46B

91B

Apertura anterior

67.85

Cierre anterior

62.08

Noticias sobre sentimiento de mercado

By Acuity

67%

33%

316 / 348 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Boston Scientific Corp. Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

22 abr 2026, 11:22 UTC

Ganancias

Boston Scientific 1Q Net Grows Sharply, Company Cuts 2026 Adjusted EPS View

4 feb 2026, 16:14 UTC

Ganancias
Principales Movimientos del Mercado

Boston Scientific Plunges on Disappointing 1Q Outlook Despite 4Q Earnings Beat

4 feb 2026, 12:13 UTC

Ganancias

Boston Scientific Sees More Growth after Earnings, Sales Rise

22 abr 2026, 11:07 UTC

Ganancias

Boston Scientific 1Q Net Grows Sharply, Company Cuts 2026 Adj EPS View

22 abr 2026, 10:32 UTC

Ganancias

Boston Scientific Now Sees 2026 Reported Sales Up 7%-8.5%, Organic Sales Up 6.5%-8% >BSX

22 abr 2026, 10:31 UTC

Ganancias

Boston Scientific Sees 2Q Reported Sales Up 5.5%-7.5%, Organic Sales Up 5%-7% >BSX

22 abr 2026, 10:30 UTC

Ganancias

Boston Scientific 1Q Organic Sales Up 9.4% >BSX

22 abr 2026, 10:30 UTC

Ganancias

Boston Scientific 1Q Adj EPS 80c >BSX

22 abr 2026, 10:30 UTC

Ganancias

Boston Scientific 1Q EPS 90c >BSX

22 abr 2026, 10:30 UTC

Ganancias

Boston Scientific 1Q Sales $5.2B >BSX

22 abr 2026, 10:30 UTC

Ganancias

Boston Scientific Sees 2Q Adj EPS 82c-Adj EPS 84c >BSX

22 abr 2026, 10:30 UTC

Ganancias

Boston Scientific Sees FY Adj EPS $3.34-Adj EPS $3.41 >BSX

30 mar 2026, 15:34 UTC

Charlas de Mercado

Boston Scientific Faces Some Slowing Growth Trends -- Market Talk

4 feb 2026, 21:41 UTC

Ganancias

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 feb 2026, 19:38 UTC

Ganancias

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 feb 2026, 17:32 UTC

Ganancias

These Stocks Are Today's Movers: AMD, AbbVie, Eli Lilly, Boston Scientific, MP Materials, Super Micro, Silicon Labs, Uber, and More -- Barrons.com

4 feb 2026, 15:30 UTC

Ganancias

Boston Scientific Earnings Beat Estimates. It's the Worst Stock in the S&P 500 Today. -- Barrons.com

4 feb 2026, 15:29 UTC

Ganancias

These Stocks Are Today's Movers: AMD, Eli Lilly, AbbVie, Uber, Super Micro, Enphase, Boston Scientific, and More -- Barrons.com

4 feb 2026, 14:06 UTC

Ganancias

Boston Scientific Profit, Sales Rise but Issues Soft Guidance -- Update

4 feb 2026, 13:58 UTC

Ganancias

Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply. -- Barrons.com

4 feb 2026, 13:12 UTC

Ganancias

Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply. -- Barrons.com

4 feb 2026, 11:32 UTC

Ganancias

Boston Scientific Sees 2026 Sales Up 10.5%-11.5%, Organic Sales Up 10%-11% >BSX

4 feb 2026, 11:31 UTC

Ganancias

Boston Scientific Sees 1Q Sales Up 10.5%-12%, Organic Sales Up 8.5%-10% >BSX

4 feb 2026, 11:30 UTC

Ganancias

Boston Scientific 4Q Organic Sales Up 12.7% >BSX

4 feb 2026, 11:30 UTC

Ganancias

Boston Scientific Sees 2026 Adj EPS $3.43-Adj EPS $3.49 >BSX

4 feb 2026, 11:30 UTC

Ganancias

Boston Scientific Sees 1Q Adj EPS 78c-Adj EPS 80c >BSX

4 feb 2026, 11:30 UTC

Ganancias

Boston Scientific 4Q Adj EPS 80c >BSX

4 feb 2026, 11:30 UTC

Ganancias

Boston Scientific 4Q Sales $5.29B >BSX

4 feb 2026, 11:30 UTC

Ganancias

Boston Scientific 4Q EPS 45c >BSX

24 ene 2026, 06:18 UTC

Adquisiciones, fusiones, absorciones

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

Comparación entre iguales

Cambio de precio

Boston Scientific Corp. previsión

Precio Objetivo

By TipRanks

45.64% repunte

Estimación a 12 Meses

Media 90.4 USD  45.64%

Máximo 118 USD

Mínimo 71 USD

De acuerdo con 27 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Boston Scientific Corp. Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

27 ratings

26

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

102.95 / 104.93Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

No Evidence

Sentimiento

By Acuity

316 / 348 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.